Clin2
NCT03862859Possibly a fitRecruiting

Warfarin safety for people with atrial fibrillation on dialysis

Atrial Fibrillation and FlutterStrokeMajor BleedEnd-stage Renal Disease

Treatments studied

Part of Brain & nervous system, Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.

This trial studies whether the blood thinner warfarin is safe and effective for preventing stroke and blood clots in people who have atrial fibrillation and need long-term dialysis. It may help your care team better balance clot prevention against bleeding risk.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
718 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Be 18 or older and on long-term (chronic) dialysis for kidney failure
  • Have atrial fibrillation that is paroxysmal (comes and goes), persistent, or permanent, confirmed on an ECG or a heart monitor
  • Be able to understand the study and sign informed consent
  • Have a CHA2DS2-VASc score of 2 or higher (not 0 or 1)
  • Not need blood thinners for another reason (for example, a recent pulmonary embolism or deep vein clot, or a mechanical heart valve)
  • Not have major bleeding risks recently (for example: active bleeding, recent brain bleed, stomach ulcer in the last month, esophageal varices, or an unsafe platelet/liver problem)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05679024Recruiting· Phase 3
Apixaban to prevent stroke in atrial fibrillation and kidney failure

This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.

Helsinki
NCT06949319Recruiting
Stroke Risk and Blood Clots in New Atrial Fibrillation

This study looks at stroke risk and blood clotting in people who have just been diagnosed with atrial fibrillation (AFib) that is not caused by a heart valve problem, and who have not yet taken blood thinners. It aims to better understand how blood clots form in this condition.

Esbjerg, Region Syddanmark
NCT05204212Recruiting
Heart procedure to close an atrial clot risk pouch in kidney failure

This trial tests a heart procedure that closes a part of the heart called the left atrial appendage to help prevent stroke in people with an irregular heartbeat (atrial fibrillation) and very advanced kidney disease. It’s mainly for patients who can take the needed blood-thinner medicines and who do not already have a clot in that pouch.

Lübeck, Schleswig-Holstein
NCT06402851Recruiting· Phase 4
Blood thinner or none for atrial fibrillation with dialysis

This trial compares two types of blood thinners (vitamin K antagonists and factor Xa inhibitors) versus no blood thinner in people with atrial fibrillation who are on dialysis or have very advanced kidney disease. It aims to see which option is safest and most effective for preventing strokes and bleeds.

Salvador, Estado de Bahia
NCT07779746Not yet recruiting· Phase 3
Blood thinner or not for irregular heartbeat on dialysis

This study compares two ways to manage atrial fibrillation (an irregular heartbeat) in people on dialysis. One approach uses a blood thinner called apixaban, and the other does not use blood thinners. The goal is to see which approach better prevents strokes and bleeding.

NCT06045858Not yet recruiting· Phase 3
Comparing apixaban and warfarin for peritoneal dialysis patients with atrial fibrillation

This trial compares two blood thinners, apixaban and warfarin, in people on peritoneal dialysis who have atrial fibrillation (an irregular heartbeat). The goal is to see which one works better and is safer for preventing strokes.

Hear when a new Atrial Fibrillation and Flutter trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.